Intellectual Property
Our intellectual property is critical to our business, and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We also rely on trade secrets and proprietary know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
For our product candidates, we have pursued patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional method of use, process of making, formulation and dosing regimen-related claims.
In total, our patent portfolio, including our owned patents and patent applications, those licensed and sublicensed and co-owned, comprises nineteen different patent families, filed in various jurisdictions worldwide, including families directed to: (1) our proprietary pre|CISION® technology, including compositions of matter for fibroblast activated protein (FAP)-activated peptide drug conjugates (PDC) and related methods of treating cancer; and (2) our proprietary Affimer® technology, including compositions of matter for certain Affimer® agents and Affimer® drug conjugates (AffDC) and related methods of treating cancer. Our patent portfolio includes issued patents in the United States, Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Singapore, and Taiwan.
Additionally, we own multiple pending United States provisional patent applications directed to our recently disclosed pipeline, including our AVA6103 program (pre|CISION® FAP-cleavable peptide attached to a camptothecin warhead via a novel linker that modulates and extends the release of the warhead from the conjugated molecule) and our AVA7100 program (pre|CISION® FAP-cleavable non-internalizing FAP-binding Affimer® drug conjugate (AffDC) attached to an undisclosed warhead via a novel linker that will release the warhead specifically in the tumor microenvironment) with four pending United States provisional patent applications.
For more information on Avacta’s IP portfolio, please contact us.